ClinicalTrials.gg
CompletedNCT05553808Updated Jan 19, 2023Results posted

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

A Phase 2 interventional study of Docetaxel and Feladilimab in Neoplasms, sponsored by GlaxoSmithKline. Completed at 43 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Jan 2019, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 105 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving signed /assent.
  • Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.
  • Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and

    a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD[L]1) monoclonal antibody (mAb) containing regimen.

    b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.

    c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria

  • , presenting with at least 1 measurable lesion per RECIST 1.1.
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, is acceptable.
  • Adequate organ function as defined in the protocol.
  • A male participant must agree to use a highly effective during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:

    i) Not a woman of (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.

  • of at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):

    1. Docetaxel at any time.
    2. Any of the agents being tested in the current study.
    3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.
    4. Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.
  • Received greater than (>)2 for NSCLC, including participants with BRAF molecular alternations.
  • Invasive or history of invasive malignancy other than disease under study within the last 2 years, except

    • Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.
    • Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.
  • Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) .
  • Major surgery less than or equal to (\<=) 28 days of first dose of study treatment.
  • disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.
  • Receiving systemic steroids (>10 milligrams [mg]) oral prednisone or equivalent) or other agents within 7 days prior to first dose of study treatment.
  • Prior allogeneic/autologous bone marrow or solid organ transplantation.
  • Receipt of any within 30 days prior to first dose of study treatment.
  • Toxicity from previous anticancer treatment that includes:

    1. Greater than or equal to (>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.
    2. Toxicity related to prior treatment that has not resolved to \<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<= Grade 2).
  • History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include

    1. Serious, uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third degree atrioventricular block.
    2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.
    3. Symptomatic pericarditis.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy \<=7 days prior to first dose of study treatment.
  • Participants with known infection.
  • Participants with history of severe to mAb or hypersensitivity to any of the study treatment(s) or their .
  • Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 () enzymes.
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator.
  • Pregnant or lactating female participants.
  • Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.
  • Participants with presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.
  • Receipt of transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Docetaxel

    Drug: Docetaxel

  • Experimental
    Feladilimab plus Docetaxel

    Drug: Docetaxel · Drug: Feladilimab

Interventions

  • Docetaxel was administered as IV infusion.

  • Feladilimab was administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was calculated as time from randomization to death. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Up to 2 years

Secondary outcomes

  1. Kaplan-Meier Estimates of Overall Survival at 12 and 18 Months

    Overall survival was defined as the time between date of randomization and death due to any cause. Kaplan-Meier estimates of the percentage of participants who died at each time point was calculated. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Month 12 and 18

  2. Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD) or Not Evaluable

    CR, PR, SD and PD will be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to 2 years

  3. Kaplan-Meier Estimates of Progression-Free Survival (PFS)

    PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Up to 2 years

  4. Objective Response Rate

    ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to 2 years

  5. Kaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response

    DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Up to 2 years

  6. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: Up to 2 years

  7. Number of Participants With iRECIST Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), Stable Disease (iSD) or Not Evaluable

    Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.

    Time frame: Up to 2 years

  8. Kaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS)

    iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Up to 2 years

  9. iRECIST Objective Response Rate (iORR)

    iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to 2 years

  10. Kaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response

    iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.

    Time frame: Up to 2 years

  11. Number of Participants With AEs, Adverse Events of Special Interest (AESI), SAEs and AE/SAEs Leading to Dose Modifications/Delays/Withdrawals

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology.

    Time frame: Up to 2 years

  12. Number of Participants With Maximum Grade Increase in Clinical Chemistry Parameters at Worst Case Post-Baseline

    Blood samples were collected for assessment of the clinical chemistry parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with clinical chemistry results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.

    Time frame: Up to 2 years

  13. Number of Participants With Maximum Grade Increase in Hematology Parameters at Worst Case Post-Baseline

    Blood samples were collected for assessment of the hematology parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with Hematology results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.

    Time frame: Up to 2 years

  14. Number of Participants With Maximum Grade Increase in Vital Signs (Systolic Blood Pressure and Diastolic Blood Pressure) Parameters at Worst Case Post-Baseline

    Blood Pressure was measured after 5 minutes of rest and was taken in the same position throughout the study. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE. Number of participants with vital signs results by maximum grade increase (Increase to Grade 2 or Increase to Grade 3) are presented.

    Time frame: Up to 2 years

  15. Number of Participants With Vital Signs (Temperature) Parameter Results at Worst Case Post-Baseline

    Body temperature was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<=35 Degrees Celsius, Change to Normal or No Change and Increase to \>=38 Degrees Celsius.

    Time frame: Up to 2 years

  16. Number of Participants With Vital Signs (Pulse Rate) Parameter Results at Worst Case Post-Baseline

    Pulse Rate was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<50 beats per minute, Change to Normal or No Change and Increase to \>120 beats per minute.

    Time frame: Up to 2 years

  17. Minimum Observed Concentration (CmIn) of Feladilimab

    Blood samples were collected for assessment of the pharmacokinetic parameters.

    Time frame: Week 1

  18. Maximum Observed Concentration (Cmax) of Feladilimab

    Blood samples were collected for assessment of the pharmacokinetic parameters.

    Time frame: Week 1, Week 13 and Week 25

  19. Maximum Observed Concentration (Cmax) of Docetaxel

    Blood samples were collected for assessment of the pharmacokinetic parameters.

    Time frame: Week 1, Week 4, Week 7, Week 10, Week 13, Week 16, Week 19 and Week 22

  20. Number of Participants With Positive Anti-drug Antibodies (ADA) Against Docetaxel

    Time frame: Up to 2 years

  21. Number of Participants With Positive ADA Against Feladilimab

    Time frame: Week 1, 4, 7, 10, 13, 16, 19, 22, 25, 37, 49, 61 and 73

07

Results

Posted Jan 19, 2023

Participant flow

Participant flow — Overall Study
MilestoneDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Started3570
Completed00
Not completed3570
Withdrew: Death2562
Withdrew: Site closed66
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject32

Outcome measures

PrimaryOverall Survival

Overall survival was calculated as time from randomization to death. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Overall Survival
MonthsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Overall Survival8.2 (4.5 to 16.1)7.8 (4.7 to 10.8)
SecondaryKaplan-Meier Estimates of Overall Survival at 12 and 18 Months

Overall survival was defined as the time between date of randomization and death due to any cause. Kaplan-Meier estimates of the percentage of participants who died at each time point was calculated. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Month 12 and 18
Reported as:
Number · Percentage of Participants
Kaplan-Meier Estimates of Overall Survival at 12 and 18 Months
Percentage of ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Month 1244 (27 to 60)28 (18 to 39)
Month 1828 (14 to 44)18 (10 to 28)
SecondaryNumber of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD) or Not Evaluable

CR, PR, SD and PD will be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD) or Not Evaluable
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Complete Response00
Partial Response413
Stable Disease1022
Progressive Disease1423
Not Evaluable712
SecondaryKaplan-Meier Estimates of Progression-Free Survival (PFS)

PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Kaplan-Meier Estimates of Progression-Free Survival (PFS)
MonthsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m2
Kaplan-Meier Estimates of Progression-Free Survival (PFS)3.3 (1.6 to 4.2)3.4 (2.6 to 4.3)
SecondaryObjective Response Rate

ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m2
Objective Response Rate11 (3.2 to 26.7)19 (10.3 to 29.7)
SecondaryKaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response

DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Kaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response
MonthsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Kaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response4.8 (2.8 to NA)4.3 (2.4 to 8.7)
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Disease Control Rate (DCR)40 (23.9 to 57.9)50 (37.8 to 62.2)
SecondaryNumber of Participants With iRECIST Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), Stable Disease (iSD) or Not Evaluable

Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With iRECIST Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), Stable Disease (iSD) or Not Evaluable
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
iCR00
iPR413
iUPD1115
iCPD38
iSD1022
Not Evaluable712
SecondaryKaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS)

iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Kaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS)
MonthsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m2
Kaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS)3.3 (1.6 to 4.2)3.4 (2.6 to 4.3)
SecondaryiRECIST Objective Response Rate (iORR)

iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of Participants
iRECIST Objective Response Rate (iORR)
Percentage of ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
iRECIST Objective Response Rate (iORR)11 (3.2 to 26.7)19 (10.3 to 29.7)
SecondaryKaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response

iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Kaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response
MonthsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Kaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response4.8 (2.8 to NA)4.3 (2.4 to 8.7)
SecondaryNumber of Participants With AEs, Adverse Events of Special Interest (AESI), SAEs and AE/SAEs Leading to Dose Modifications/Delays/Withdrawals

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With AEs, Adverse Events of Special Interest (AESI), SAEs and AE/SAEs Leading to Dose Modifications/Delays/Withdrawals
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
AEs3470
AESI14
SAEs1634
AEs leading to permanent discontinuation of study treatment1216
AEs leading to dose reduction713
AEs leading to dose interruption/delay1124
SecondaryNumber of Participants With Maximum Grade Increase in Clinical Chemistry Parameters at Worst Case Post-Baseline

Blood samples were collected for assessment of the clinical chemistry parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with clinical chemistry results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade Increase in Clinical Chemistry Parameters at Worst Case Post-Baseline
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Blood bilirubin increased01
Hypercalcemia02
Creatinine increased01
SecondaryNumber of Participants With Maximum Grade Increase in Hematology Parameters at Worst Case Post-Baseline

Blood samples were collected for assessment of the hematology parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with Hematology results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade Increase in Hematology Parameters at Worst Case Post-Baseline
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Anemia25
Leukocytosis01
White blood cell decreased511
Lymphocyte count decreased412
Neutrophil count decreased413
Platelet count decreased03
SecondaryNumber of Participants With Maximum Grade Increase in Vital Signs (Systolic Blood Pressure and Diastolic Blood Pressure) Parameters at Worst Case Post-Baseline

Blood Pressure was measured after 5 minutes of rest and was taken in the same position throughout the study. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE. Number of participants with vital signs results by maximum grade increase (Increase to Grade 2 or Increase to Grade 3) are presented.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade Increase in Vital Signs (Systolic Blood Pressure and Diastolic Blood Pressure) Parameters at Worst Case Post-Baseline
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Diastolic Blood Pressure1226
Systolic Blood Pressure1628
SecondaryNumber of Participants With Vital Signs (Temperature) Parameter Results at Worst Case Post-Baseline

Body temperature was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<=35 Degrees Celsius, Change to Normal or No Change and Increase to \>=38 Degrees Celsius.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs (Temperature) Parameter Results at Worst Case Post-Baseline
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Decrease to <=35 Degrees Celsius06
Change to Normal or No Change3352
Increase to >=38 Degrees Celsius15
SecondaryNumber of Participants With Vital Signs (Pulse Rate) Parameter Results at Worst Case Post-Baseline

Pulse Rate was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<50 beats per minute, Change to Normal or No Change and Increase to \>120 beats per minute.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs (Pulse Rate) Parameter Results at Worst Case Post-Baseline
ParticipantsDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Decrease to <50 beats per minute00
Change to Normal or No Change3255
Increase to >120 beats per minute28
SecondaryMinimum Observed Concentration (CmIn) of Feladilimab

Blood samples were collected for assessment of the pharmacokinetic parameters.

Time frame:
Week 1
Reported as:
Geometric mean · nanogram per millimeter (ng/mL)
Minimum Observed Concentration (CmIn) of Feladilimab
nanogram per millimeter (ng/mL)Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Minimum Observed Concentration (CmIn) of Feladilimab6104.6 ± 91.3
SecondaryMaximum Observed Concentration (Cmax) of Feladilimab

Blood samples were collected for assessment of the pharmacokinetic parameters.

Time frame:
Week 1, Week 13 and Week 25
Reported as:
Geometric mean · nanogram per millimeter (ng/mL)
Maximum Observed Concentration (Cmax) of Feladilimab
nanogram per millimeter (ng/mL)Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Week 124923.7 ± 26.7
Week 1328715.9 ± 45.4
Week 2532688.4 ± 27.4
SecondaryMaximum Observed Concentration (Cmax) of Docetaxel

Blood samples were collected for assessment of the pharmacokinetic parameters.

Time frame:
Week 1, Week 4, Week 7, Week 10, Week 13, Week 16, Week 19 and Week 22
Reported as:
Geometric mean · nanogram per millimeter (ng/mL)
Maximum Observed Concentration (Cmax) of Docetaxel
nanogram per millimeter (ng/mL)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
Week 11500.9 ± 133.51429.9 ± 138.7
Week 41587.1 ± 128.61399.7 ± 99.3
Week 7846.8 ± 166.41036.9 ± 171.2
Week 101262.9 ± 155.41248.4 ± 118.3
Week 131354.2 ± 212.11363.4 ± 137.8
Week 161095.3 ± 114.31381.9 ± 114.0
Week 19759.0 ± 74.01765.7 ± 95.1
Week 22535.5 ± 10.92430.7 ± 73.3
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) Against Docetaxel
Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Positive ADA Against Feladilimab
Time frame:
Week 1, 4, 7, 10, 13, 16, 19, 22, 25, 37, 49, 61 and 73
Reported as:
Count of participants · Participants
Number of Participants With Positive ADA Against Feladilimab
ParticipantsFeladilimab 80 mg Plus Docetaxel 75 mg/m^2
Week 11
Week 48
Week 74
Week 102
Week 132
Week 161
Week 192
Week 220
Week 250
Week 370
Week 490
Week 610
Week 730

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected up to 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel 75 mg/m^225/34 (73.5%)16/34 (47.1%)31/34 (91.2%)
Feladilimab 80 mg Plus Docetaxel 75 mg/m^262/70 (88.6%)34/70 (48.6%)66/70 (94.3%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
PneumoniaInfections and infestations6/347/70
Febrile neutropeniaBlood and lymphatic system disorders3/344/70
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/343/70
Diarrhoea infectiousInfections and infestations1/340/70
Lung abscessInfections and infestations1/340/70
Pneumocystis jirovecii pneumoniaInfections and infestations1/340/70
Pneumonia mycoplasmalInfections and infestations1/340/70
AnaemiaBlood and lymphatic system disorders1/342/70
PneumonitisRespiratory, thoracic and mediastinal disorders1/342/70
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/341/70
Most frequent other events
Showing 10 of 48
Most frequent other events
EventDocetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2
NauseaGastrointestinal disorders6/3426/70
AnaemiaBlood and lymphatic system disorders7/3424/70
DyspnoeaRespiratory, thoracic and mediastinal disorders4/3423/70
AstheniaGeneral disorders10/3422/70
AlopeciaSkin and subcutaneous tissue disorders7/3420/70
Decreased appetiteMetabolism and nutrition disorders4/3419/70
FatigueGeneral disorders5/3417/70
DiarrhoeaGastrointestinal disorders8/3416/70
CoughRespiratory, thoracic and mediastinal disorders4/3414/70
ConstipationGastrointestinal disorders2/3413/70

Baseline characteristics

Age, Continuous
Age, Continuous(years)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2Total
Mean62.6 ± 10.4864.4 ± 9.1163.8 ± 9.57
Age, Customized
Age, Customized(Participants)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2Total
18-64223153
65-7472835
75-8451116
>=85101
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2Total
Female81725
Male275380
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2Total
Hispanic or Latino022
Not Hispanic or Latino3567102
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Docetaxel 75 mg/m^2Feladilimab 80 mg Plus Docetaxel 75 mg/m^2Total
Canada303
South Korea459
Netherlands033
Sweden022
Romania2911
United States5712
Poland134
Italy4711
France6915
Germany3710
Spain41317
Russia358
08

Study locations

43 sites
  • GSK Investigational Site
    Saint Louis, Missouri 63110-1093, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Bordeaux Cedex, 33076, France
  • GSK Investigational Site
    Caen Cedex 9, 14033, France
  • GSK Investigational Site
    Nantes cedex 1, 44093, France
  • GSK Investigational Site
    Paris Cedex 05, 75248, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Villejuif Cedex, 94805, France
  • GSK Investigational Site
    Gauting, Bayern, Germany
  • GSK Investigational Site
    Immenhausen, Hessen 34376, Germany
  • GSK Investigational Site
    Leipzig, Sachsen, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Berlin, 14165, Germany
  • GSK Investigational Site
    Meldola (FC), Emilia-Romagna 47014, Italy
  • GSK Investigational Site
    Ravenna, Emilia-Romagna 48121, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
  • GSK Investigational Site
    Orbassano (TO), Piemonte 10043, Italy
  • GSK Investigational Site
    Cheongju-si, 28644, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 10408, Korea, Republic of
  • GSK Investigational Site
    Seongnam, 13620, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05505, Korea, Republic of
  • GSK Investigational Site
    Maastricht, 6229 HX, Netherlands
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Warszawa, 02-781, Poland
  • GSK Investigational Site
    Bucharest, 020142, Romania
  • GSK Investigational Site
    Craiova, 200347, Romania
  • GSK Investigational Site
    Floresti, 407280, Romania
  • GSK Investigational Site
    Otopeni, 075100, Romania
  • GSK Investigational Site
    Timisoara, 300166, Romania
  • GSK Investigational Site
    Chelyabinsk, 454048, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 194291, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 197183, Russian Federation
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Sevilla, 41009, Spain
  • GSK Investigational Site
    Uppsala, SE- 75 185, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Sep 2021, 31 months.

Results were first posted in Jan 2023, 1 year 3 months after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 31 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Jan 24, 2019
Primary completionActual
Sep 23, 2021
CompletionActual
Sep 23, 2021
Results first posted
Jan 19, 2023
Last update
Jan 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05553808
Lead sponsor
GlaxoSmithKline
Collaborators
iTeos Belgium SA
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Jan 24, 2019
Primary completion
Sep 23, 2021
Completion
Sep 23, 2021
Results posted
Jan 19, 2023
Last update
Jan 19, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion